I am thrilled to take this new role at Avacta and lead us into the next chapter

#LetsDoThis
#PeptidesCreateHope

Preliminary Results for the Year Ended 31 December 2023. avacta.com/preliminary-re… #AVCT

Avacta announces that Christina Coughlin, MD, PhD, has been appointed as the new Chief Executive Officer of Avacta. avacta.com/christina-coug… #AVCT

In the second episode of our R&D Spotlight series we are fast forwarding into the clinic and talking to two members of the Avacta translational medicine team. avacta.wistia.com/medias/x1pkwnv… #AVCT #PeptidesCreateHope

Avacta will announce its audited preliminary results for year ended 31st December 2023 on 30th April 2024. avacta.com/notice-of-resu… #AVCT

If you missed Avacta CEO Alastair Smith's presentation and Q&A in yesterday's Turner Pope webinar, you can watch it back here: turnerpope.com/investor-eveni… #AVCT .

New frontiers in exploiting stroma for therapy. FAP directed precision medicine. Phase I of AVA600 showing tolerability, plasmas/tumour PK and clinical proof of concept response in FAP high tumours. Abstract CT188 #AACR2024 The ICR The Royal Marsden NHS Foundation Trust ECMC Network

Our presentation at #AACR24 today - well received with many intriguing conversations.

Grateful and humbled by our lead author Prof udaibanerji who did not stop speaking for 3.5 hours. Udai - much appreciated

#PeptidesCreateHope
#LetsDoThis

The Royal Marsden NHS Foundation Trust The ICR

Our April newsletter is now live: consiliumsc.activehosted.com/index.php?acti…

Featuring insights from Christina Coughlin, MD, PhD, Head of R&D at Avacta on the AACR Annual Meeting and Dr Danuta Jeziorska, CEO and Co-Founder of Nucleome Therapeutics on World DNA Day.

#ICRConsilium #Newsletter

AVA6000 Abstract Release by AACR and Full Presentation Update. avacta.com/ava6000-abstra… #AVCT

Avacta's Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on Wednesday, 10 April 2024 at 5:30pm (BST). More info on how to register can be found here: avacta.com/investor-webin… #AVCT

In the new R&D Spotlight Series we will take you a little deeper into the science behind the Avacta Therapeutics pipeline. In the first episode today we're going to introduce you to two of our key chemists who are working on the preCISION platform. avacta.wistia.com/medias/1h18nhz… #AVCT

Update on AVA6000 Phase 1a Clinical Trial Progress. avacta.com/update-on-ava6… #AVCT

Result of General Meeting. avacta.com/result-of-gene… #AVCT

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024. avacta.com/updated-result… #AVCT

Result of REX Retail Offer. avacta.com/result-of-rex-… #AVCT